Eli Lilly beats Novo Nordisk to launch weight-loss drug Mounjaro in India, at $50 for 5 mg vial
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Novo Nordisk to Pay $2 Billion for New Weight Loss Drug
TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
NDTV Profit1d
Eli Lilly's Weight-Loss Drug Mounjaro Gets Thumbs Up From JM Financial — Here's Why
JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
'Ozempic-like' weight loss drug Mounjaro creates buzz amid India launch: Price per month, availability, pros and cons
Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...
Zacks.com on MSN1d
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
Open to tie-ups in India for selling Mounjaro: Eli Lilly CEO David Ricks
Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...
Weight-loss drug Mounjaro now in India: What is the price? What are the side effects? Here's all you need to know
Eli Lilly launched its diabetes and weight-loss drug Mounjaro in India, ahead of Novo Nordisk, aiming at a market grappling ...
NBC Chicago2d
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk's blockbuster obesity injection Wegovy and diabetes treatment Ozempic activate GLP-1. Meanwhile, Eli Lilly's weight loss drug Zepbound and diabetes treatment Mounjaro target both GLP ...